ATLASATLAS fair value
ATLAS has no fair value for this stock today.
InterCure (INCR)
InterCure stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
$4.47▲ +4.68%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
39%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on InterCure in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On InterCure
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives InterCure a 39% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $2.92 and $5.35; in 9 out of 10, between $1.70 and $9.16. Estimated annual volatility is 200%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $81.3M
- 52-week high
- $6.10
- 52-week low
- $0.68
- Revenue (12 months)
- $270M
- Revenue growth (YoY)
- +13.1%
- Gross margin
- 12.3%
- Operating margin
- 2.5%
- Net margin
- -13.6%
- Return on equity
- -9.3%
- Free cash flow (12 months)
- $-12.2M
- Beta
- 0.60
What this means
ATLAS does not publish a fair value for INCR right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks INCR has traded between $0.68 and $6.10. Today it is 26.7% below that high and 557% above its low.
On the business: revenue grew 13.1% year over year; net margin is 13.6%.
Its beta is 0.60: it tends to move less than the market.
About the company
InterCure Ltd. is an Israel-based pharmaceutical cannabis company focused on the production, manufacturing, and distribution of medical cannabis products.
Want to see everything about InterCure?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does InterCure do?
InterCure Ltd. is an Israel-based pharmaceutical cannabis company focused on the production, manufacturing, and distribution of medical cannabis products.
What is the chance INCR goes up next month?
39%: somewhat worse than a coin flip. In half of the simulated outcomes, INCR ends the month between $2.92 and $5.35.
How big is InterCure and what is its P/E ratio?
InterCure's market capitalization is $81.3M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is INCR?
ATLAS estimates annual volatility at 200%. In a typical month, half of the outcomes end between $2.92 and $5.35.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer